You have free access to this content

Cancer

Cover image for Cancer

1 April 2002

Volume 94, Issue 7

Pages 1907–2117

  1. In Memoriam

    1. Top of page
    2. In Memoriam
    3. Original Articles
    4. Correspondence
    5. Erratum
    1. You have free access to this content
  2. Original Articles

    1. Top of page
    2. In Memoriam
    3. Original Articles
    4. Correspondence
    5. Erratum
    1. Disease Site

      Breast
      You have free access to this content
      Multicentric mammary carcinoma : Evidence of monoclonal proliferation (pages 1910–1916)

      Lavinia P. Middleton, George Vlastos, Nadeem Q. Mirza, S. Eva Singletary and Aysegul A. Sahin

      Article first published online: 28 MAR 2002 | DOI: 10.1002/cncr.10452

      In the current study, the authors report the clinicopathologic findings of 32 cases of multicentric mammary carcinoma. The histologies of these 31 cases were similar and the immunohistochemical findings were qualitatively the same for estrogen receptor, progesterone receptor, HER-2/neu, and Ki-67, suggesting that these tumors have a clonal origin. No appreciable difference with regard to disease-free survival was found between early-stage patients with multicentric mammary carcinoma and matched patients with unicentric carcinoma.

    2. You have free access to this content
      The value of breast lumpectomy margin assessment as a predictor of residual tumor burden in ductal carcinoma in situ of the breast (pages 1917–1924)

      Andrew C. Neuschatz, Thomas DiPetrillo, Margaret Steinhoff, Homa Safaii, Michael Yunes, Marcia Landa, Maureen Chung, Blake Cady and David E. Wazer

      Article first published online: 28 MAR 2002 | DOI: 10.1002/cncr.10460

      Margin width is considered the most important risk factor for local recurrence in ductal carcinoma in situ (DCIS) of the breast. In this study of 253 DCIS cases with lumpectomy and reexcision, the authors assessed the predictive utility of lumpectomy specimen margin assessment for the presence and extent of residual DCIS. They evaluated probability of residual tumor with respect to tumor size, margin status, nuclear grade, presence of necrosis, patient age, and the extent of specimen processing. On multivariate analysis, they found that margin width and lesion size on initial excision remained significant predictors of both the presence and amount of residual tumor.

    3. You have free access to this content
      A Phase II study of paclitaxel by 24-hour infusion and ifosfamide in anthracycline-resistant metastatic breast carcinoma (pages 1925–1930)

      Jae H. Seo, Young M. Whang, Byung S. Kim, Chul W. Choi, Sang W. Shin, Yeul H. Kim, Jun S. Kim and Bum H. Goo

      Article first published online: 28 MAR 2002 | DOI: 10.1002/cncr.10431

      Combination chemotherapy of paclitaxel by 24-hour infusion and ifosfamide is effective and well tolerated in anthracycline-resistant metastatic breast carcinoma patients. Further well designed comparative studies exploiting this regimen with more patients are warranted to verify the authors' results and the clinical feasibility of this regimen as a frontline treatment to the patients with advanced disease.

    4. Gastrointestinal Tract
      You have free access to this content
      Efficacy and toxicity of adjuvant chemotherapy in elderly patients with colon carcinoma : A 10-year experience of the Geisinger Medical Center (pages 1931–1938)

      Farid Fata, Ayoub Mirza, G. Craig Wood, Suresh Nair, Amy Law, James Gallagher, Neil Ellison and Albert Bernath

      Article first published online: 28 MAR 2002 | DOI: 10.1002/cncr.10430

      In the current study, the authors reviewed their experience with the safety and efficacy of adjuvant chemotherapy in elderly patients with Stage II and Stage III carcinoma of the colon. Such therapy for these elderly patients well tolerated and achieves benefits similar to those observed in younger patients.

    5. You have free access to this content
      Expression of UDP-N-acetyl-α-D-galactosamine–polypeptide galNAc N-acetylgalactosaminyl transferase-3 in relation to differentiation and prognosis in patients with colorectal carcinoma (pages 1939–1946)

      Kazunori Shibao, Hiroto Izumi, Yoshifumi Nakayama, Ryo Ohta, Naoki Nagata, Minoru Nomoto, Ken-ichi Matsuo, Yuji Yamada, Kenji Kitazato, Hideaki Itoh and Kimitoshi Kohno

      Article first published online: 28 MAR 2002 | DOI: 10.1002/cncr.10423

      The expression of UDP-N-acetyl-α-D-galactosamine–polypeptide GalNAc N-acetylgalactosaminyl transferase-3 (GalNAc-T3) enzyme protein was studied in 106 resected colorectal carcinoma specimens and was correlated with tumor differentiation and depth of tumor invasion. Patients who had tumors with strong GalNAc-T3 expression had better survival rates. A multivariate Cox survival analysis identified GalNAc-T3 enzyme expression as an independent prognostic factor that was second only to TNM stage among six major prognostic variables. The authors concluded that GalNAc-T3 was useful for evaluating tumor differentiation, invasiveness, and prognosis in patients with colorectal carcinoma.

    6. You have free access to this content
      Prognostic significance of serum thymidine phosphorylase concentration in esophageal squamous cell carcinoma (pages 1947–1954)

      Hideaki Shimada, Akihiko Takeda, Tooru Shiratori, Yoshihiro Nabeya, Shin-ichi Okazumi, Hisahiro Matsubara, Yutaka Funami, Hideki Hayashi, Yoshio Gunji, Susumu Kobayashi, Takao Suzuki and Takenori Ochiai

      Article first published online: 28 MAR 2002 | DOI: 10.1002/cncr.10418

      Thymidine phosphorylase (dThdPase) is a potent angiogenic factor in tumors. This study analyzes the prognostic significance of serum dThdPase concentration in patients with esophageal squamous cell carcinoma.

    7. You have free access to this content
      Expression and prognostic significance of PTEN product protein in patients with esophageal squamous cell carcinoma (pages 1955–1960)

      Mitsuo Tachibana, Muneaki Shibakita, Satoshi Ohno, Shoichi Kinugasa, Hiroshi Yoshimura, Shuhei Ueda, Toshiyuki Fujii, Mohammad A. Rahman, Dipok K. Dhar and Naofumi Nagasue

      Article first published online: 4 APR 2002 | DOI: 10.1002/cncr.0678

      Nuclear expression of PTEN product protein may be a favorable biologic marker and a useful prognostic indicator in patients with esophageal squamous cell carcinoma.

    8. Gynecologic Oncology
      You have free access to this content
      Performance status rather than age is the key prognostic factor in second-line treatment of elderly patients with epithelial ovarian carcinoma (pages 1961–1967)

      Bo Gronlund, Claus Høgdall, Heine H. Hansen and Svend A. Engelholm

      Article first published online: 28 MAR 2002 | DOI: 10.1002/cncr.10385

      Newer intravenous cytostatic agents as second-line treatment of epithelial ovarian carcinoma are withheld from many elderly patients because of fear of toxicity. In a retrospective analysis of 102 patients receiving intravenous second-line treatment with topotecan or paclitaxel-carboplatin, no differences in overall survival or overall response rates nor number of toxicity events between comparable groups of older (older than 65 years) and younger (younger than 65 years) patients were noticed (P > 0.05). Modern intravenous cytostatics in second-line treatment can be safely administered in the aged.

    9. Head and Neck Disease
      You have free access to this content
      Prognostic value of p53 mutations, bax, and spontaneous apoptosis in maxillary sinus squamous cell carcinoma (pages 1968–1980)

      Nobuyuki Bandoh, Tatsuya Hayashi, Kan Kishibe, Miki Takahara, Masanobu Imada, Satoshi Nonaka and Yasuaki Harabuchi

      Article first published online: 28 MAR 2002 | DOI: 10.1002/cncr.10388

      Mutation of the p53 tumor suppressor gene, the expression of apoptosis-related proteins, and clinical outcomes were analyzed in 70 patients with maxillary sinus squamous cell carcinoma. A low level of spontaneous apoptosis as well as p53 mutation at the pretreatment period was correlated with low histologic effectiveness of radiochemotherapy and with poor prognosis.

    10. You have free access to this content
      Detection of recurrent or persistent nasopharyngeal carcinomas after radiotherapy with technetium-99m methoxyisobutylisonitrile single photon emission computed tomography and computed tomography : Comparison with 18-fluoro-2-deoxyglucose positron emission tomography (pages 1981–1986)

      Chia-Hung Kao, Yu-Chien Shiau, Yeh-You Shen and Ruoh-Fang Yen

      Article first published online: 28 MAR 2002 | DOI: 10.1002/cncr.10400

      The diagnostic accuracy of technetium-99m methoxyisobutylisonitrile single photon emission computed tomography and computed tomography of the head and neck, for differentiating recurrent or residual nasopharyngeal carcinomas (NPC) from benign lesions after radiotherapy, was compared with the diagnostic accuracy of positron emission tomography with 18-fluoro-2-deoxyglucose in 36 NPC patients.

    11. You have free access to this content
      Definition of three minimal deleted regions by comprehensive allelotyping and mutational screening of FHIT,p16INK4A, and p19ARF genes in nasopharyngeal carcinoma (pages 1987–1996)

      Jenq-Yuh Ko, Tso-Ching Lee, Chin-Fu Hsiao, Guan-Lu Lin, Sang-Hue Yen, Kuang Y. Chen, Chao A. Hsiung, Pei-Jer Chen, Mow-Ming Hsu and Yuh-Shan Jou

      Article first published online: 28 MAR 2002 | DOI: 10.1002/cncr.10406

      In the current study, comprehensive allelotyping on chromosome 3, 9, and 11 of nasopharyngeal carcinoma (NPC) samples revealed three minimal deleted regions (MDRs) on chromosome 3p25.3-24.1 (< 19 centimorgans [cM]), 3p23-21.31 (< 9 cM), and 11q22.1-23.2 (< 8 cM). In addition, a single point mutation on the intron 1 splicing acceptor site of the INK4a/ARF locus in NPC cell lines was found to result in exon 2 skipping both p16INK4a and p19ARF transcripts that presumably inactivate the functions of both p16INK4a and p19ARF proteins.

    12. You have free access to this content
      Molecular pathology parameters in human nasopharyngeal carcinoma (pages 1997–2006)

      Wei Shi, Istvan Pataki, Christine MacMillan, M. Pintilie M.Sc., David Payne, Brian O'Sullivan M.B., Bernard J. Cummings M.B. Ch.B., Padraig Warde and Fei-Fei Liu

      Article first published online: 4 APR 2002 | DOI: 10.1002/cncr.0679

      The authors evaluated several molecular variables to examine the hypothesis that p53 dysfunction in nasopharyngeal carcinoma (NPC) is associated with Epstein-Barr virus (EBV), increased tumor angiogenesis, lower likelihood of apoptosis, and poorer clinical outcome. p53 protein was over-expressed in approximately one third of NPC samples in the current study, and this correlated significantly with the presence of EBV encoded RNA. Epstein-Barr virus status was also associated with World Health Organization type 3 NPC, Asian/Chinese ethnicity, and induction of p21. The presence of EBV appeared to predict for improved survival.

    13. You have free access to this content
      Site specific dependency of second primary cancer in early stage head and neck squamous cell carcinoma (pages 2007–2014)

      Eiji Yamamoto, Hitoshi Shibuya, Ryo-ichi Yoshimura and Masahiko Miura

      Article first published online: 28 MAR 2002 | DOI: 10.1002/cncr.10444

      Site specific differences in the incidence of second primary cancer after treatment for early stage head and neck squamous cell carcinoma result in different prognoses, depending on the primary site.

    14. Hematologic Malignancies
      You have free access to this content
      Changing incidence of non-Hodgkin lymphomas in the United States (pages 2015–2023)

      Christina A. Clarke and Sally L. Glaser

      Article first published online: 28 MAR 2002 | DOI: 10.1002/cncr.10403

      To look at incidence trends in non-Hodgkin lymphoma (NHL) among age, gender, and race specific population subgroups in the United States over the last several decades, the authors have used 1973–1998 cancer surveillance data and newly developed joinpoint regression methods that examine rate changes over time. Rates decreased 6–16% per year in the middle to late 1990s among males aged 25–54 years, with rates in blacks now exceeding rates in whites; and rate increases slowed from 3–4% to 1–2% per year in the late 1980s among most whites aged ≥ 55 years.

    15. You have free access to this content
      Simultaneous homoharringtonine and interferon-α in the treatment of patients with chronic-phase chronic myelogenous leukemia (pages 2024–2032)

      Susan O'Brien, Moshe Talpaz, Jorge Cortes, Jianqin Shan, Francis J. Giles, Stefan Faderl, Deborah Thomas, Guillermo Garcia-Manero, Susie Mallard, Mary Beth Rios, Charles Koller, Steve Kornblau, Michael Andreeff, Anthony Murgo, Michael Keating and Hagop M. Kantarjian

      Article first published online: 28 MAR 2002 | DOI: 10.1002/cncr.10436

      Forty-seven patients with Philadelphia chromosome (Ph) positive chronic myelogenous leukemia (CML) were treated with a combination of homoharringtonine (HHT) and interferon-α (IFN-α). The complete hematologic response rate was 85%, and the cytogenetic response rate was 66%, with major responses (Ph < 35%) in 49% of patients and complete responses (Ph = 0%) in 21% of patients. The estimated 2-year survival rate was 90%. The outcome of elderly patients was favorable. Toxicities were manageable with dose adjustments (median daily IFN-α dose, 1 MU/m2; median days on HHT, 2 days per month), but anemia was significant and was responsive to erythropoietin.

    16. You have free access to this content
      Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma : Implications for clinical trials in this patient population (pages 2033–2039)

      Jeremy G. Perkins, Joseph M. Flynn, Robin S. Howard and John C. Byrd

      Article first published online: 4 APR 2002 | DOI: 10.1002/cncr.0680

      Fludarabine refractory chronic lymphocytic leukemia/small lymphocytic lymphoma patients are prone to serious infections regardless of therapy given. This needs to be considered when investigating new therapies to prevent abandonment of such agents due to a perceived excess of infectious toxicity.

    17. Hepatobiliary Tract
      You have free access to this content
      Combined hepatocellular and cholangiocarcinoma : Demographic, clinical, and prognostic factors (pages 2040–2046)

      William R. Jarnagin, Sharon Weber, Satish K. Tickoo, Jonathan B. Koea, Sam Obiekwe, Yuman Fong, Ronald P. DeMatteo, Leslie H. Blumgart and David Klimstra

      Article first published online: 28 MAR 2002 | DOI: 10.1002/cncr.10392

      Tumors with histopathologic features of hepatocellular and cholangiocellular differentiation (combined tumors) are less likely to arise in the setting of cirrhosis than are hepatocellular carcinomas. Resection is associated with long-term survival in some patients but, as with hepatocellular carcinoma and peripheral cholangiocarcinoma, intrahepatic recurrence is common.

    18. You have free access to this content
      Frequent impairment of the spindle assembly checkpoint in hepatocellular carcinoma (pages 2047–2054)

      Ayuko Saeki, Shinji Tamura, Nobuyuki Ito, Shinichi Kiso, Yasuo Matsuda, Iwao Yabuuchi, Sumio Kawata and Yuji Matsuzawa

      Article first published online: 28 MAR 2002 | DOI: 10.1002/cncr.10448

      The impairment of the spindle assembly checkpoint occurred with a high frequency in hepatocellular carcinoma with aneuploidy and might be critical for hepatocarcinogenesis and tumor growth.

    19. Lung Disease
      You have free access to this content
      Trimodality treatment in Stage III nonsmall cell lung carcinoma : Prognostic impact of K-ras mutations after neoadjuvant therapy (pages 2055–2062)

      Petra Broermann, Klaus Junker, Burkhard H. Brandt, Achim Heinecke, Lutz Freitag, Folker Klinke, Wolfgang E. Berdel and Michael Thomas

      Article first published online: 28 MAR 2002 | DOI: 10.1002/cncr.10387

      In a trimodality treatment approach of Stage III nonsmall cell lung carcinoma, the proof of a K-ras codon 12 point mutation in the resection specimens is a significant predictor for a poor progression free survival, even in patients with complete tumor resection.

    20. Neuro-Oncology
      You have free access to this content
      Prediction of intracranial metastases in cancer patients with headache (pages 2063–2068)

      Maria H. Christiaans, Johannes C. Kelder, Edo P. J. Arnoldus and Cees C. Tijssen

      Article first published online: 28 MAR 2002 | DOI: 10.1002/cncr.10379

      In the current study, the incidence of intracranial metastases in cancer patients presenting with new or changed headache of recent onset was 32.4%. A prediction model for intracranial metastases that contains 3 clinical predictors (i.e., headache duration of ≤ 10 weeks, emesis, and pain not of tension-type) is presented. Because of low specificity, a magnetic resonance imaging scan of the brain still is warranted in these patients.

    21. Sarcoma
      You have free access to this content
      Tumor specific gene expression profiles in human leiomyosarcoma : An evaluation of intratumor heterogeneity (pages 2069–2075)

      Ilya Shmulevich, Kelly Hunt, Adel El-Naggar, Ellen Taylor, Latha Ramdas, Pilar Labordé, Kenneth R. Hess, Raphael Pollock and Wei Zhang

      Article first published online: 28 MAR 2002 | DOI: 10.1002/cncr.10425

      Computational analysis of gene expression profiles in patients with leiomyosarcoma suggests that intratumor heterogeneity is similar to the observed experimental variability of replicate experiments, implying minimal impact on molecular profiling.

    22. Discipline

      Integrated Medicine
      You have free access to this content
      Treatment decisions for breast carcinoma : Patient preferences and physician perceptions (pages 2076–2080)

      Eduardo Bruera, Jie S. Willey, J. Lynn Palmer and Marguerite Rosales

      Article first published online: 28 MAR 2002 | DOI: 10.1002/cncr.10393

      Women with breast carcinoma have a strong desire to be involved in making decisions regarding their treatment. However, physicians do not always predict patients' decision-making preferences accurately.

    23. Pediatric Oncology
      You have free access to this content
      High incidence of thyroid dysfunction despite prophylaxis with potassium iodide during 131I-meta-iodobenzylguanidine treatment in children with neuroblastoma (pages 2081–2089)

      Hanneke M. van Santen, Jan de Kraker, Berthe L. F. van Eck, Jan J. M. de Vijlder and Thomas Vulsma

      Article first published online: 28 MAR 2002 | DOI: 10.1002/cncr.10447

      In spite of administration of KI during treatment with 131I-meta-iodobenzylguanidine for neuroblastoma in 42 patients, 52.4% developed thyroid dysfunction. The current article presents a retrospective analysis of the underlying causes and consequences.

    24. You have free access to this content
      The PedsQL™ in pediatric cancer : Reliability and validity of the pediatric quality of life inventory™ generic core scales, multidimensional fatigue scale, and cancer module (pages 2090–2106)

      James W. Varni, Tasha M. Burwinkle, Ernest R. Katz, Kathy Meeske and Paige Dickinson

      Article first published online: 28 MAR 2002 | DOI: 10.1002/cncr.10428

      Pediatric Quality of Life Inventory (PedsQL) is a modular instrument designed to measure health-related quality of life in children and adolescents ages 2–18 years. The results of this study demonstrate the reliability and validity of the PedsQL Generic Core Scales, Multidimensional Fatigue Scale, and Cancer Module in pediatric cancer. The PedsQL may be used as an outcome measure in clinical trials, research, and clinical practice.

    25. Translational Research
      You have free access to this content
      Increased proliferative activity caused by loss of p21WAF1/CIP1 expression and its clinical significance in patients with early-stage gastric carcinoma (pages 2107–2112)

      Hiroshi Noda, Yoshihiko Maehara, Koji Irie, Yoshihiro Kakeji, Tomohiro Yonemura and Keizo Sugimachi

      Article first published online: 28 MAR 2002 | DOI: 10.1002/cncr.10417

      The authors suggest that the loss of p21 expression in patients with early-stage gastric carcinoma contributes to increases in proliferative activity, as estimated by proliferating cell nuclear antigen levels. Patients with early-stage gastric carcinoma who have high proliferative activity should be followed closely.

  3. Correspondence

    1. Top of page
    2. In Memoriam
    3. Original Articles
    4. Correspondence
    5. Erratum
    1. You have free access to this content
    2. You have free access to this content
      Clinicopathologic implications of E-cadherin reactivity in patients with lobular carcinoma in situ of the breast (pages 2114–2115)

      Jorge S. Reis-Filho, Joana Cancela Paredes, Fernanda Milanezi and Fernando C. Schmitt

      Article first published online: 21 SEP 2010 | DOI: 10.1002/cncr.0681

    3. You have free access to this content
      Author reply (pages 2115–2116)

      Neal S. Goldstein

      Article first published online: 28 MAR 2002 | DOI: 10.1002/cncr.10411

  4. Erratum

    1. Top of page
    2. In Memoriam
    3. Original Articles
    4. Correspondence
    5. Erratum
    1. You have free access to this content
      Erratum (page 2117)

      T Kimura, H Suzuki, T Ohashi, K Asano, H Kiyota and Y Eto

      Article first published online: 28 MAR 2002 | DOI: 10.1002/cncr.10582

SEARCH

SEARCH BY CITATION